Xin'an (Lenalidomide Capsules) _Oncology_Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

中

中文 English

About Us
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
News
- Company News
- Media Focus
- With the objective of 'creating excellence in China's pharmaceuticals and add momentum to "Made in China"',Hansoh endeavors to make its own contribution to the “Healthy China 2030” master plan.
- With the objective of 'creating excellence in China's pharmaceuticals and add momentum to "Made in China"',Hansoh endeavors to make its own contribution to the “Healthy China 2030” master plan.
Products
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
R&D
- Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
- Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
- Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
- Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
Services
- Hansoh pursuits the philosophy of “Professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate marketing systems
- Hansoh pursuits the philosophy of “Professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate marketing systems
- Hansoh pursuits the philosophy of “Professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate
Contact Us
- Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.



Xin'an (Lenalidomide Capsules)

Lenalidomide Capsules

English Name: Lenalidomide Capsules

Chinese Pinyin: Lainadu’an Jiaonang

The main ingredient of this product is lenalidomide.

Chemical Name: 3-(4-amino-1-oxo-1,3-dihydro-2H-isoindole-2-yl)piperidine-2,6-dione

/en/upload/images/2021/06/17/69029c9dab224c7d823f9324c8034503.png

【Name】	Common Name: Lenalidomide Capsules English Name: Lenalidomide Capsules Chinese Pinyin: Lainadu’an Jiaonang
【Ingredients】	Main Ingredient: lenalidomide Chemical Name: 3-(4-amino-1-oxo-1,3-dihydro-2H-isoindole-2-yl) piperidine-2,6-dione Structural Formula: Molecular Formula: C₁₃H₁₃N₃O₃ Molecular Weight: 259.26
【Description】	The content of this product is white or off-white powder.
【Indication】	This product is used in combination with dexamethasone to treat adult patients with previously untreated multiple myeloma who are not candidates for transplantation. This product is used in combination with dexamethasone to treat adult patients with multiple myeloma who have received at least one previous therapy.
【Strength】	25mg.
【Dosage and Administration】	Therapeutic dosing must be initiated and provided under the supervision of a physician with experience in the treatment of multiple myeloma. This product should not be initiated if the patient has an absolute neutrophil count (ANC) < 1.0×109/L and/or a platelet count < 50×109/L. Recommended Dose The recommended starting dose of this product is 25mg, Take 25mg of this product orally every day on days 1 to 21 of each repeated 28-day cycle until disease progression. The recommended dose of dexamethasone is 40mg orally on days 1, 8, 15, and 22 of each 28-day treatment cycle. The prescriber should select the starting dose and subsequent dose adjustment of dexamethasone according to the patient's age (see Table 1). Table 1: Determination of starting dose of dexamethasone by age Note: Please refer to the Product Manual for details.